Divalproex Sodium Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Divalproex Sodium Market Analysis
The divalproex sodium market is projected to register a CAGR of 6.2% during the forecast period, 2022-2027.
The COVID-19 pandemic has been continuing to transform the growth of various markets, and the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. For instance, according to an article published in March 2020 titled "Epilepsy and COVID-19: Updated Evidence and Narrative Review," a survey of 212 pediatric neurologists from 49 countries found that in-person outpatient visits have decreased, and telemedicine use was increased during the pandemic. Thus, COVID-19 has a significant impact on the growth of the market in the initial phase. However, the demand for divalproex sodium is expected to rise at a considerable pace in the coming years.
Moreover, the major factors responsible for the growth of the divalproex sodium market include the growing incidence rates of bipolar disorders, rising patient pool with epilepsy and migraine headaches, increasing government initiatives, and rising research and development to introduce new products.
The increasing prevalence of bipolar disorders worldwide is propelling market growth. As per an article titled 'What is the worldwide prevalence of bipolar disorder?' published in October 2021, bipolar disorder has a lifetime prevalence of about 1% and a one-year prevalence of about 0.5% worldwide. Bipolar I disorder has greater rates than bipolar II disorder.According to World Health Organization (WHO) key facts updated in June 2022, 1 in every 8 people in the world live with a mental disorder. Due to the COVID-19 pandemic, the number of people who suffer from anxiety and depressive illnesses greatly increased in 2020. Initial projections indicate a 26% and 28% increase in depressive disorders and anxiety, respectively, in just one year. As per the same source, in 2020, 40 million people experienced bipolar disorder.
Moreover, globally, the expanding patient pool affected with epilepsy and migraine headaches is also expected to significantly boost the demand in the divalproex sodium market. For instance, as per the World Health Organization's update of February 2022, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. In high-income countries, there are an estimated 49 per 100,000 patients that are diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000. Such a high burden of epilepsy creates the need for treatment and thus drives the growth of the market.
Furthermore, the increasing awareness regarding diseases and various government initiatives to prevent migraines are expected to propel the growth of the divalproex sodium market. For instance, in November 2021, in the United States, November is celebrated as National Epilepsy Awareness Month (NEAM). Every year, the Epilepsy Foundation, in collaboration with the Epilepsy Foundation, launches the #RemoveTheFilter social media campaign to reduce fear surrounding epilepsy and bring hope to those facing challenges. Such awareness campaigns are also expected to contribute to the growth of the market.
However, black boxed warning given by the Food and Drug Administration due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablet and other known adverse reactions such as birth defects, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth.
Divalproex Sodium Market Trends
This section covers the major market trends shaping the Divalproex Sodium Market according to our research experts:
Epilepsy and Migraine Headaches Segment is Expected to Account for the Largest Market Share During the Forecast Period
Epilepsy is one of the most common nervous system disorders that cause seizures. When there is an enduring predisposition to seizures, it is called epilepsy. It can affect people of any age, ranging from children to adults, across all races and backgrounds. For instance, according to the World Health Organization's February 2022 update, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. Therefore, the increasing incidences of epilepsy cases across the globe are expected to increase the demand for epilepsy monitoring devices as they provide critical insights into the type of seizures. Furthermore, various organizations are raising awareness about epilepsy in the United States. For instance, Epilepsy Awareness Day, or Purple Day, is celebrated annually on the 26th of March to increase the public's understanding of this brain disorder and to eliminate the fear and stigma surrounding it.
Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. Migraine is one of the world's most common health conditions and it's a common neurological disease. According to American Migraine Foundation data updates from June 2022, it is the third most common disease affecting 1 out of every 7 people globally. It affects almost 37 million people in the United States, and it is estimated that 148 million people will suffer from the disease in the coming years across the world. Therefore, due to the increasing incidence of migraine, the demand for divalproex sodium for treating migraine is expected to increase which will propel the market growth.
In the present scenario, people's lifestyles have induced anxiety and stress in their daily lives. Thus, the patient pool affected by epilepsy and migraine headaches is expected to increase during the forecast period and contribute as a driving factor to the growth of the divalproex sodium market.
North America is Expected to Hold a Significant Market Share During the Forecast Period
In North America, the United States divalproex sodium market holds the major share. Increased government initiatives and rising research and development activities aimed at launching new products are expected to aid the growth of the divalproex sodium market in the region. According to the article titled "Epidemiology of status epilepticus in the United States: A systematic review" published in November 2020, the incidence of all status epilepticus in patients of all ages in the United States ranged from 18.3 to 41 per 100,000 people per year. Such a high burden of epilepsy has contributed to the increase in the demand for divalproex sodium to provide treatment to patients.
Moreover, according to the article published in the JAMA Network in January 2022, titled 'What Is Migraine?', in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, higher prevalence is expected to boost the growth of the market in the United States.
Furthermore, in February 2022, Unichem Laboratories received Abbreviated New Drug Application (ANDA) approval for its Divalproex Sodium extended-release tablets from the United States Food and Drug Administration (US FDA). Such advancements are expected to drive the market's growth over the forecast period.
Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period.
Divalproex Sodium Industry Overview
The divalproex sodium market is consolidated and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that are currently dominating the market are AbbVie Inc., Zydus Cadila, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd, Lupin Pharmaceuticals Inc., Orchid Pharma Ltd, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, and Abbott Laboratories.
Divalproex Sodium Market Leaders
-
AbbVie Inc.
-
Lupin Pharmaceuticals, Inc.
-
Dr. Reddy's Laboratories Ltd.
-
Zydus Cadila
-
Aurobindo Pharma
*Disclaimer: Major Players sorted in no particular order
Divalproex Sodium Market News
- In February 2022, Unichem Laboratories received Abbreviated New Drug Application (ANDA) approval for its Divalproex Sodium extended-release tablets from the United States Food and Drug Administration (USFDA).
- In September 2020, Lupin launched the divalproex sodium extended-release tablets, USP 250 mg and 500 mg, after receiving approval from the US FDA (Food and Drug Administration).
Divalproex Sodium Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Incidence Rates of Bipolar Disorders
- 4.2.2 Expanding Patient Pool with Epilepsy and Migraine Headaches
- 4.2.3 Increasing Government Initiatives and Rising Research and Development Activities to Introduce New Products
-
4.3 Market Restraints
- 4.3.1 Stringent Regulations
- 4.3.2 Increasing Neurobehavioral Adverse Effects, Birth Defects, and Suicidal Tendencies due to Divalproex Sodium Usage
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type
- 5.1.1 Tablet
- 5.1.2 Capsule
- 5.1.3 Syrup
-
5.2 By Application
- 5.2.1 Epilepsy and Migraine Headaches
- 5.2.2 Manic-Depressive Illness
- 5.2.3 Other Applications
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Online Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Zydus Cadila
- 6.1.3 Aurobindo Pharma
- 6.1.4 Dr. Reddy's Laboratories Ltd
- 6.1.5 Lupin Pharmaceuticals Inc.
- 6.1.6 Orchid Pharma Ltd
- 6.1.7 Sun Pharmaceuticals Industries Ltd
- 6.1.8 Teva Pharmaceuticals Industries Ltd
- 6.1.9 Abbott Laboratories
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDivalproex Sodium Industry Segmentation
As per the scope of the report, divalproex sodium is an anti-epileptic drug that is prescribed to patients with bipolar disorder, migraine headaches, and certain types of seizures. This drug is known for its anticonvulsant property for the treatment of epilepsy. The divalproex sodium market is segmented by product type (tablet, capsules, and syrup), application (epilepsy, manic-depressive illness, and other applications), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type | Tablet | |
| Capsule | ||
| Syrup | ||
| By Application | Epilepsy and Migraine Headaches | |
| Manic-Depressive Illness | ||
| Other Applications | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Divalproex Sodium Market Research FAQs
What is the current Global Divalproex Sodium Market size?
The Global Divalproex Sodium Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Global Divalproex Sodium Market?
AbbVie Inc., Lupin Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila and Aurobindo Pharma are the major companies operating in the Global Divalproex Sodium Market.
Which is the fastest growing region in Global Divalproex Sodium Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Divalproex Sodium Market?
In 2024, the North America accounts for the largest market share in Global Divalproex Sodium Market.
What years does this Global Divalproex Sodium Market cover?
The report covers the Global Divalproex Sodium Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Divalproex Sodium Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Specimen Retrieval Industry Report
Statistics for the 2024 Specimen Retrieval market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Specimen Retrieval analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
